Tranexamic Acid Shortage: What Providers and Prescribers Need to Know in 2026

Tranexamic acid (TXA) is a cornerstone antifibrinolytic agent used across multiple clinical settings — from heavy menstrual bleeding management to trauma resuscitation, perioperative blood conservation, and hemophilia protocols. This briefing summarizes the current availability landscape for 2026, relevant regulatory updates, therapeutic substitution guidance, and practical tools to help your patients maintain access.

Current Availability Status (2026)

Tranexamic acid oral tablets (650 mg) are not currently listed on the FDA Drug Shortages database as of 2026. Multiple generic manufacturers hold approved NDAs, including Amring Pharmaceuticals, Teva Pharmaceuticals, ANI Pharmaceuticals, and Advagen Pharma, providing a reasonably stable oral supply chain.

However, two supply-related concerns deserve provider attention:

Localized oral tablet gaps: Retail pharmacy stock is variable. Patients — particularly those in rural areas or served by small independent pharmacies — may encounter localized stock gaps despite no formal shortage.

IV formulation variability: The injectable formulation (100 mg/mL) used in surgical and trauma settings continues to face intermittent availability at the institutional level. Anesthesiology and pharmacy departments should maintain formulary contingency plans.

Historical Context: The 2020 Lysteda Discontinuation

Providers unfamiliar with the supply history should note that Ferring Pharmaceuticals discontinued Lysteda (brand-name tranexamic acid 650 mg) in 2020, triggering an ASHP-tracked shortage that lasted through mid-2021. Since resolution, the market has been supplied entirely by generic manufacturers. Prescriptions referencing "Lysteda" by brand name may still occasionally cause confusion at the pharmacy level; providers should confirm their prescriptions specify generic tranexamic acid 650 mg tablets.

2025 FDA Safety Update: Injectable TXA

In 2025, the FDA issued enhanced safety communications and required labeling revisions for tranexamic acid injection. These changes strengthened warnings regarding the risk of inadvertent neuraxial (intrathecal or epidural) administration, which has caused catastrophic outcomes including seizures, prolonged hospitalization, paralysis, and death. Key changes include:

Updated Boxed Warning: TXA injection is for IV use only. Intrathecal and epidural administration are formally contraindicated.

Storage protocols required: Facilities using TXA intraoperatively should store it separately from local anesthetics and spinal drugs, with clear labeling.

Practice implication: Ambulatory surgery centers and inpatient anesthesiology departments should review and update TXA protocols in line with 2025 FDA guidance.

Therapeutic Substitution Options by Indication

If tranexamic acid is unavailable for a specific patient, substitution options vary by indication:

Heavy Menstrual Bleeding (HMB)

Aminocaproic acid (Amicar): Most direct antifibrinolytic substitute. Dose conversion: TXA 1,300 mg TID × 5 days → EACA approximately 5 g PO QID × 5 days. Note: oral solution availability is variable.

Levonorgestrel IUD (Mirena/Liletta): Long-term alternative for appropriate patients; reduces HMB by >90%. Not appropriate for immediate/urgent cycle management.

Combined oral contraceptives or progestins: Appropriate for patients without contraindications to hormonal therapy.

NSAIDs (ibuprofen, naproxen): Modest ~20-30% HMB reduction; appropriate adjunct for mild-moderate cases without platelet dysfunction.

Hemophilia / Bleeding Disorders

Aminocaproic acid (IV or oral): Acceptable substitute for dental/surgical hemostasis in hemophilia. Coordinate with hematology.

Desmopressin (DDAVP): Appropriate for responsive patients with mild hemophilia A or VWD (types 1, 2A, 2M, 2N). Confirm desmopressin responsiveness before use.

Factor replacement therapy: For patients with moderate-severe hemophilia or those unresponsive to antifibrinolytics.

Perioperative / Trauma Settings

Aminocaproic acid (IV): EACA IV can substitute for TXA IV in many surgical hemostasis protocols. Higher doses required (loading dose 4-5 g IV, then 1 g/hr infusion vs. TXA 10-15 mg/kg protocols).

Postpartum hemorrhage: TXA 1 g IV remains the WHO-recommended agent. If unavailable, immediate escalation to uterotonic agents and obstetric intervention is warranted. There is no equivalent single substitute for TXA in massive postpartum hemorrhage.

Helping Patients Access Tranexamic Acid

When your outpatient patients report difficulty filling their tranexamic acid prescription, you can direct them to medfinder for Providers. medfinder calls pharmacies in the patient's area to identify which can fill the prescription, then delivers results by text. This reduces prescription abandonment due to out-of-stock situations and saves staff time on patient access troubleshooting.

Key Recommendations for Prescribers

Write prescriptions for "generic tranexamic acid 650 mg" — avoid specifying "Lysteda" to prevent pharmacy confusion.

Offer 90-day mail-order prescriptions for stable outpatient HMB patients to reduce monthly access barriers.

Review 2025 FDA safety updates for injectable TXA and ensure your facility's storage and administration protocols are compliant.

Proactively document an alternative agent (aminocaproic acid, hormonal therapy, or desmopressin as appropriate) in care plans for patients dependent on TXA.

Check FDA and ASHP drug shortage databases periodically for updated status on both oral and injectable formulations.

Summary

Tranexamic acid oral tablets have a stable supply nationally in 2026, but localized gaps and injectable formulation variability remain concerns for active prescribers. Staying proactive — providing substitution plans and directing patients to access tools like medfinder — reduces the clinical impact of any disruptions. For a detailed guide on helping your patients locate tranexamic acid, see our provider guide to helping patients find tranexamic acid in stock.